uracil and taxane
uracil has been researched along with taxane in 5 studies
Research
Studies (5)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Barton, CM; Bonneterre, J; Cirkel, DT; Davidson, NG; Piccart, MJ; Richel, DJ; Skovsgaard, T | 1 |
Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H | 1 |
Colwell, B; Conklin, HS; Frye, D; Graham, M; Hortobagyi, GN; Levin, J; McGuirt, C; Rivera, E; Somerville, M; Sutton, L | 1 |
Fujimura, Y; Miyayama, H; Nagao, K; Nakagawa, K; Nishimura, R; Okazaki, S | 1 |
Hirakawa, K; Ishikawa, T; Kato, Y; Nakata, B; Ogawa, Y; Onoda, N; Takagaki, K; Takashima, T | 1 |
Trials
2 trial(s) available for uracil and taxane
Article | Year |
---|---|
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Treatment Outcome; Uracil | 2001 |
Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Patient Compliance; Taxoids; Treatment Outcome; Uracil | 2002 |
Other Studies
3 other study(ies) available for uracil and taxane
Article | Year |
---|---|
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Topics: Aminoacridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Disease Models, Animal; Drug Combinations; Female; Floxuridine; Humans; Lung Neoplasms; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Taxoids; Tegafur; Uracil | 2002 |
[A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Drug Combinations; Epirubicin; Female; Humans; Lung Neoplasms; Mastectomy, Segmental; Middle Aged; Receptor, ErbB-2; Taxoids; Tegafur; Trastuzumab; Uracil | 2003 |
[A case of anthracycline and taxane-resistant breast cancer with life-thereatening multiple liver metastases responding to oral combination chemotherapy by UFT, cyclophosphamide and medroxyprogesterone acetate].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Taxoids; Tegafur; Uracil | 2005 |